Reta Stock News

Investors need to pay close attention to Reata (RETA) stock based on the movements in the options market lately.

Morgan Stanley raised its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 9.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,580 shares of the companys stock after purchasing an additional 6,193 shares during the period. Morgan Stanley owned approximately 0.19% [] The post Morgan Stanley Buys 6,193 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) appeared first on ETF Daily News .

MADDEN SECURITIES Corp lowered its holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,127 shares of the companys stock after selling 1,675 shares during the quarter. Reata Pharmaceuticals accounts for about 1.8% of []

Wall Street analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to announce ($2.58) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Reata Pharmaceuticals earnings, with the highest EPS estimate coming in at ($2.27) and the lowest estimate coming in at ($2.89). Reata Pharmaceuticals reported earnings per share []

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (Reata, the Company, our, us, or we), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreichs ataxia. We are pleased to receive Fast Track Designation as it highlights the potential

Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) dropped 6% on Monday . The stock traded as low as $96.22 and last traded at $96.26. Approximately 1,201 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 324,692 shares. The stock had previously closed at $102.45. The company has a 50 []

Metropolitan Life Insurance Co NY raised its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 376,450.0% in the second quarter, Holdings Channel.com reports. The firm owned 7,531 shares of the companys stock after buying an additional 7,529 shares during the period. Metropolitan Life Insurance Co NYs holdings in Reata Pharmaceuticals were worth $1,066,000 as []

Weiss Multi Strategy Advisers LLC lowered its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 10.0% in the second quarter, Holdings Channel reports. The firm owned 2,476 shares of the companys stock after selling 276 shares during the period. Weiss Multi Strategy Advisers LLCs holdings in Reata Pharmaceuticals were worth $350,000 at the end []

Credit Suisse AG increased its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 2.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,699 shares of the companys stock after purchasing an additional 705 shares during the period. Credit Suisse AGs holdings in []

Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q3 2021 Financial Results and Update on Development Programs (Transcript)

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 15.09% and 427.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q3 earnings results on Monday, November 8, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.

PLANO, Texas--(BUSINESS WIRE)---- $RETA--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it w

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts high